• Henriette Røed-Undlien, Nina Haagenrud Schultz, Asbjørn Lunnan, Inger Marie Husebråten, Birgit Malene Wollmann, Espen Molden, and Johannes Lagethon Bjørnstad.
• Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
• J. Cardiothorac. Vasc. Anesth. 2022 Jun 1; 36 (6): 163616441636-1644.

ObjectivesThe use of unopposed oral anticoagulants while undergoing cardiothoracic surgery is associated with severe bleeding and increased morbidity. The aim of this experimental study was to examine if the apixaban concentration in reconstituted blood could be reduced in an in vitro setup by the use of CytoSorb whole blood adsorber, and to study how this affected global coagulation assays.Design And SettingAn experimental study performed in a laboratory.ParticipantsAn in vitro setup with reconstituted whole blood.InterventionsReconstituted whole blood spiked with apixaban circulated in an in vitro circuit with the CytoSorb 300 mL device connected.Measurements And Main ResultsBlood samples were drawn at 0, 5, 15, 30, 60, and 120 minutes of adsorption. The apixaban concentration was measured at each time point. In addition, the global coagulation assays, thromboelastometry clotting time and thrombin generation, were performed, and the results were compared with baseline values obtained before spiking blood with apixaban. After 30 minutes of adsorption, the mean apixaban concentration was reduced from 414.3 (±69.1) ng/mL to 33 (±11.4) ng/mL. Thrombin generation showed maximum effect after 60 minutes, and the thromboelastometry clotting time was close to baseline values after 120 minutes.ConclusionsIn this in vitro study, apixaban concentrations were effectively reduced, and the clotting time and thrombin generation assays were normalized by the use of CytoSorb whole blood adsorber.Copyright © 2022 The Author(s). Published by Elsevier Inc. All rights reserved.

12 keywords...

hide…